PPAR : a dagger in the heart of the metabolic syndrome

Obesity is a growing threat to global health by virtue of its association with insulin resistance, glucose intolerance, hypertension, and dyslipidemia, collectively known as the metabolic syndrome or syndrome X. The nuclear receptors PPARalpha and PPARgamma are therapeutic targets for hypertriglyceridemia and insulin resistance, respectively, and drugs that modulate these receptors are currently in clinical use. More recent work on the less-described PPAR isotype PPARdelta has uncovered a dual benefit for both hypertriglyceridemia and insulin resistance, highlighting the broad potential of PPARdelta in the treatment of metabolic disease. PPARdelta enhances fatty acid catabolism and energy uncoupling in adipose…

• HH
  Howard Hughes Medical Institute

  Award: Ronald M. Evans
• MO
  March of Dimes Foundation

  Award: Ronald M. Evans
• LL
  Larry L. Hillblom Foundation
• NI
  National Institutes of Health

  Awards: DK62434, U19DK62434
• UO
  University of California, San Diego
• NI
  National Institute of Diabetes and Digestive and Kidney Diseases

  Award: DK071